|
|
|
Search for: "Biogen"
ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer
HSMN NewsFeed,
18 Aug 2010:
Biopharmaceuticals, Oncology, FDA
[ImmunoGen, lorvotuzumab mertansine, lung cancer]
|
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
HSMN NewsFeed,
7 Jul 2010:
Biopharmaceuticals, Personnel
[Acorda Therapeutics]
|
Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
HSMN NewsFeed,
22 Jun 2010:
Biopharmaceuticals, Generics, FDA
[Hospira, meropenem, AstraZeneca, Merrem]
|
Galera Therapeutics Secures Funding for New Cancer Treatment
HSMN NewsFeed,
15 Jun 2010:
Biopharmaceuticals, Oncology, Venture Capital
[BioGenerator, Galera Therapeutics, dismutase mimetics]
|
Biogen Idec Provides Update on CEO Search and Management Changes
HSMN NewsFeed,
7 Jun 2010:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Trubion Pharmaceuticals Wins Genentech and Biogen Idec Patent Appeal
HSMN NewsFeed,
3 Jun 2010:
Biopharmaceuticals, Litigation
[Trubion Pharmaceuticals, Genentech, Biogen Idec, CD20, rheumatoid arthritis]
|
Alnylam Strengthens Management Team with New Key Appointments
HSMN NewsFeed,
2 Jun 2010:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis
HSMN NewsFeed,
19 May 2010:
Biopharmaceuticals
[Biogen Idec, Roche Group, ocrelizumab, rheumatoid arthritis]
|
Infinity Announces Senior Management Promotion
HSMN NewsFeed,
18 May 2010:
Biopharmaceuticals, Personnel
[Infinity Pharmaceuticals]
|
Taligen Announces Key Additions to Management Team
HSMN NewsFeed,
15 Apr 2010:
Biopharmaceuticals, Personnel
[Taligen Therapeutics]
|
Taligen Appoints Industry Leader, John Maraganore, as Director
HSMN NewsFeed,
15 Apr 2010:
Biopharmaceuticals, Personnel
[Taligen Therapeutics]
|
Declaratory Relief Complaint for Patent Infringement Under Patent Based on Manufacture, Marketing and Sale of Arzerra
HSMN NewsFeed,
25 Mar 2010:
Biopharmaceuticals, Oncology, Litigation
[Genmab, Genentech, Biogen Idec, GlaxoSmithKline, Arzerra, CLL]
|
Rib-X Appoints Mark Leuchtenberger as President and CEO
HSMN NewsFeed,
23 Mar 2010:
Biopharmaceuticals, Personnel
[Rib-X Pharmaceuticals]
|
Promedior Closes $12 Million Series C Financing
HSMN NewsFeed,
16 Mar 2010:
Biopharmaceuticals, Venture Capital
[Promedior]
|
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
HSMN NewsFeed,
22 Feb 2010:
Biopharmaceuticals, Personnel
[Acorda Therapeutics]
|
NeurogesX Announces Management Team Promotions
HSMN NewsFeed,
4 Feb 2010:
Biopharmaceuticals, Personnel
[NeurogesX]
|
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed,
3 Feb 2010:
Biopharmaceuticals, Neurology
[Acorda Therapeutics, AMPYRA, dalfampridine, multiple sclerosis]
|
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
HSMN NewsFeed,
25 Jan 2010:
Biopharmaceuticals, Personnel
[Acorda Therapeutics, AMPYRA, dalfampridine]
|
Biogen Idec Issues Statement on U.S. Approval of AMPYRA (dalfampridine)
HSMN NewsFeed,
23 Jan 2010:
Biopharmaceuticals, Neurology, FDA
[Biogen Idec, AMPYRA, dalfampridine, multiple sclerosis]
|
Acorda Therapeutics Announces FDA Approval of AMPYRA (dalfampridine) to Improve Walking in People with Multiple Sclerosis - Demonstrated by Increases in Walking Speed
HSMN NewsFeed,
22 Jan 2010:
Biopharmaceuticals, Neurology, FDA
[Acorda Therapeutics, AMPYRA, dalfampridine, multiple sclerosis]
|
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
HSMN NewsFeed,
20 Jan 2010:
Biopharmaceuticals, Personnel
[Constellation Pharmaceuticals, Epigenetics, epigenome]
|
Med BioGene Appoints World-Renowned Geneticist Dr. Michael R. Hayden as Director
HSMN NewsFeed,
18 Jan 2010:
Diagnostics, Personalized Medicine, Personnel
[Med BioGene]
|
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
HSMN NewsFeed,
11 Jan 2010:
Biopharmaceuticals
[Alnylam Pharmaceuticals, RNA interference, RNAi]
|
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
HSMN NewsFeed,
7 Jan 2010:
Biopharmaceuticals, Personnel
[Lycera Corp]
|
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
HSMN NewsFeed,
4 Jan 2010:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Acceleron Pharma Expands Management Team with Two New Appointments
HSMN NewsFeed,
22 Dec 2009:
Biopharmaceuticals, Personnel
[Acceleron Pharma]
|
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
HSMN NewsFeed,
17 Dec 2009:
Biopharmaceuticals, Oncology, Personnel
[ImmunoGen]
|
Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing
HSMN NewsFeed,
16 Dec 2009:
Biopharmaceuticals, Licensing, Venture Capital
[Afferent Pharmaceuticals, Roche Group, P2X31]
|
CalciMedica Achieves Milestone and Draws Down Second Tranche of $12 Million Series C Financing
HSMN NewsFeed,
15 Dec 2009:
Biopharmaceuticals, Venture Capital
[CalciMedica]
|
Ophthotech Raises $30 Million in Series B Financing
HSMN NewsFeed,
15 Dec 2009:
Biopharmaceuticals, Ophthalmology, Venture Capital
[Ophthotech]
|
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
HSMN NewsFeed,
11 Dec 2009:
Biopharmaceuticals
[Genentech, Roche Group, Biogen Idec, ocrelizumab, Rheumatoid Arthritis]
|
William D. Young to Become Chairman of Biogen Idec
HSMN NewsFeed,
10 Dec 2009:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
HSMN NewsFeed,
7 Dec 2009:
Biopharmaceuticals, Oncology
[Genentech, Roche Group, Biogen Idec, Rituxan, rituximab, leukemia]
|
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
HSMN NewsFeed,
24 Nov 2009:
Biopharmaceuticals, Personnel
[NeurogesX, Qutenza, capsaicin]
|
Receptos Completes $25M Series A Financing
HSMN NewsFeed,
23 Nov 2009:
Biopharmaceuticals, Venture Capital
[Receptos]
|
Facet Biotech's Board of Directors Recommends Stockholders Continue to Reject Biogen Idec's Tender Offer
HSMN NewsFeed,
19 Oct 2009:
Biopharmaceuticals, Mergers & Acquisitions
[Facet Biotech, Biogen Idec]
|
CalciMedica Appoints Evelyn Graham to its Board of Directors
HSMN NewsFeed,
13 Oct 2009:
Biopharmaceuticals, Personnel
[CalciMedica]
|
Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
HSMN NewsFeed,
8 Oct 2009:
Biopharmaceuticals, Generics
[Hospira, Celltrion Healthcare, biogenerics, biosimilars]
|
Amber Salzman Named President and CEO of Cardiokine
HSMN NewsFeed,
7 Oct 2009:
Biopharmaceuticals, Personnel
[Cardiokine]
|
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
HSMN NewsFeed,
17 Sep 2009:
Biopharmaceuticals, Oncology
[Genentech, Roche Group, Biogen Idec, Rituxan, rituximab]
|
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
HSMN NewsFeed,
16 Sep 2009:
Biopharmaceuticals, Oncology, Personnel
[AVEO Pharmaceuticals]
|
Elan Cures Breach of Tysabri(R) Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson
HSMN NewsFeed,
14 Sep 2009:
Biopharmaceuticals, Litigation
[Elan Corp, Tysabri, Biogen, Johnson & Johnson]
|
GENova names Dr. John Savin as Vice President
HSMN NewsFeed,
4 Sep 2009:
Biopharmaceuticals, Oncology, Personnel
[GENova Biotherapeutics]
|
Onset Therapeutics Announces Additions to Senior Management Team
HSMN NewsFeed,
27 Jul 2009:
Biopharmaceuticals, Dermatology, Personnel
[Onset Therapeutics]
|
The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor
HSMN NewsFeed,
23 Jul 2009:
Biopharmaceuticals, Personnel
[The Medicines Company]
|
Intellikine Completes $51 Million Financing
HSMN NewsFeed,
8 Jul 2009:
Biopharmaceuticals, Venture Capital
[Intellikine, mTOR]
|
Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
HSMN NewsFeed,
8 Jul 2009:
Biopharmaceuticals, Neurology, FDA
[Biogen Idec, PEGylated interferon beta-1a, interferon, multiple sclerosis]
|
Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.
HSMN NewsFeed,
1 Jul 2009:
Biopharmaceuticals, Neurology, Licensing
[Acorda Therapeutics, Biogen Idec, Fampridine-SR, multiple sclerosis]
|
Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
HSMN NewsFeed,
2 Jun 2009:
Diagnostics, Distribution
[BioGenex, Abbott, Xmatrx]
|
Celerus Diagnostics Adds International Distribution Expert to Management Team
HSMN NewsFeed,
19 May 2009:
Diagnostics, Personnel
[Celerus Diagnostics]
|
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
HSMN NewsFeed,
15 May 2009:
Biopharmaceuticals, Personnel
[Avila Therapeutics]
|
Archemix Appoints Ken Bate as President and Chief Executive Officer
HSMN NewsFeed,
6 May 2009:
Biopharmaceuticals, Personnel
[Archemix, aptamer]
|
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
HSMN NewsFeed,
5 May 2009:
Biopharmaceuticals, Personnel
[CytRx]
|
Eurand Appoints Dr. Robert Becker as Chief Research Officer
HSMN NewsFeed,
28 Apr 2009:
Biopharmaceuticals, Personnel
[Eurand]
|
Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
HSMN NewsFeed,
20 Apr 2009:
Biopharmaceuticals, Personnel
[Mpex Pharmaceuticals]
|
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
HSMN NewsFeed,
13 Apr 2009:
Biopharmaceuticals, Personnel
[Raptor Pharmaceuticals]
|
Biogen Idec Names Robert Hamm Chief Operating Officer
HSMN NewsFeed,
30 Mar 2009:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed,
11 Mar 2009:
Biopharmaceuticals
[Genentech, Biogen Idec, Rituxan, rituximab, lupus nephritis, lupus]
|
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
HSMN NewsFeed,
9 Feb 2009:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, multiple sclerosis, TYSABRI, natalizumab]
|
Arcxis Biotechnologies(R) Secures Series B Financing
HSMN NewsFeed,
30 Jan 2009:
Diagnostics, Venture Capital
[Arcxis Biotechnologies]
|
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
HSMN NewsFeed,
21 Jan 2009:
Biopharmaceuticals
[Alnylam Pharmaceuticals, RNA interference, RNAi, Herpes Simplex]
|
Alnylam Provides Update on Kreutzer-Limmer Patent Family
HSMN NewsFeed,
20 Jan 2009:
Biopharmaceuticals
[Alnylam Pharmaceuticals, RNA interference, RNAi]
|
Hydra Biosciences Raises $22 Million in Series D Financing
HSMN NewsFeed,
16 Jan 2009:
Biopharmaceuticals, Venture Capital
[Hydra Biosciences]
|
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
HSMN NewsFeed,
6 Jan 2009:
Biopharmaceuticals, Personnel
[ARIAD Pharmaceuticals]
|
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
HSMN NewsFeed,
16 Dec 2008:
Biopharmaceuticals, Oncology
[Cell Therapeutics, Spectrum Pharmaceuticals, RIT Oncology, Zevalin]
|
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
HSMN NewsFeed,
6 Dec 2008:
Biopharmaceuticals, Oncology
[Genentech, Biogen Idec, Rituxan, rituximab, chronic lymphocytic leukemia]
|
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
HSMN NewsFeed,
2 Dec 2008:
Devices, Cardiology, Personnel
[Cardiogenesis]
|
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
HSMN NewsFeed,
1 Dec 2008:
Biopharmaceuticals, Oncology
[Cell Therapeutics, Spectrum Pharmaceuticals, Zevalin]
|
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
HSMN NewsFeed,
24 Nov 2008:
Biopharmaceuticals, FDA
[Biovitrum, Syntonix Pharmaceuticals, Biogen Idec, Factor IXFc, Hemophilia]
|
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
HSMN NewsFeed,
21 Oct 2008:
Biopharmaceuticals, Personnel
[Tracon Pharmaceuticals]
|
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
HSMN NewsFeed,
8 Oct 2008:
Biopharmaceuticals, Personnel
[Calistoga Pharmaceuticals]
|
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
HSMN NewsFeed,
1 Oct 2008:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
Link Medicine Completes $40 million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders
HSMN NewsFeed,
30 Sep 2008:
Biopharmaceuticals, Venture Capital
[Link Medicine]
|
Acusphere, Inc. Appoints Michael Slater SVP Regulatory Affairs and Operations Replacing Dennis Bucceri
HSMN NewsFeed,
25 Sep 2008:
Biopharmaceuticals, Personnel
[Acusphere]
|
PDL BioPharma Names Faheem Hasnain President and Chief Executive Officer
HSMN NewsFeed,
25 Sep 2008:
Biopharmaceuticals, Personnel
[PDL BioPharma]
|
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
HSMN NewsFeed,
18 Sep 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, ASSURANCE study, AVONEX, interferon beta-1a, multiple sclerosis]
|
Teva Receives EU Marketing Authorization for TevaGrastim(R)
HSMN NewsFeed,
16 Sep 2008:
Biopharmaceuticals, Regulatory
[Teva Pharmaceutical, G-CSF, biosimilar, TevaGrastim]
|
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed,
5 Sep 2008:
Biopharmaceuticals, Oncology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, Multiple Myeloma]
|
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
HSMN NewsFeed,
3 Sep 2008:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals, Regulus Therapeutics, Isis Pharmaceuticals]
|
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
HSMN NewsFeed,
2 Sep 2008:
Biopharmaceuticals, Personnel
[Halozyme Therapeutics]
|
Monoclonal Antibody Sales to Almost Double in Coming Years
HSMN NewsFeed,
30 Aug 2008:
Biopharmaceuticals
[Monoclonal Antibody]
|
Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis
HSMN NewsFeed,
27 Aug 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, interferon beta-1a, multiple sclerosis, ASSURANCE trial]
|
Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs
HSMN NewsFeed,
25 Aug 2008:
Biopharmaceuticals, Venture Capital
[Proteostasis Therapeutics, Proteostasis Regulator]
|
Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
HSMN NewsFeed,
12 Aug 2008:
Biopharmaceuticals, FDA
[Stromedix, STX-100, orphan drug designation, chronic allograft nephropathy]
|
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
HSMN NewsFeed,
12 Aug 2008:
Biopharmaceuticals, Licensing
[ImmunoGen, sanofi-aventis, Tumor-Activated Prodrug]
|
Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
HSMN NewsFeed,
5 Aug 2008:
Biopharmaceuticals, Personnel
[Panacea Pharmaceuticals]
|
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
HSMN NewsFeed,
4 Aug 2008:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals, Regulus Therapeutics, Isis Pharmaceuticals]
|
ImmunoGen, Inc. Announces Senior Management Promotions
HSMN NewsFeed,
31 Jul 2008:
Biopharmaceuticals, Personnel
[ImmunoGen]
|
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
HSMN NewsFeed,
23 Jul 2008:
Regenerative Medicine, Personnel
[Tengion]
|
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed,
22 Jul 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis]
|
CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
HSMN NewsFeed,
1 Jul 2008:
Biopharmaceuticals, Venture Capital
[CoLucid Pharmaceuticals]
|
Biogen Idec Stockholders Elect Company's Board Nominees
HSMN NewsFeed,
19 Jun 2008:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
HSMN NewsFeed,
18 Jun 2008:
Biopharmaceuticals, Oncology
[Cell Therapeutics, Bayer Schering Pharma, Zevalin]
|
EyeGate Pharma Appoints Amy Cohen as Vice President, Clinical Operations
HSMN NewsFeed,
16 Jun 2008:
Biopharmaceuticals, Ophthalmology, Personnel
[EyeGate Pharma]
|
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
HSMN NewsFeed,
3 Jun 2008:
Biopharmaceuticals
[Sunesis Pharmaceuticals, voreloxin, SNS-595]
|
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Generics
[Follow-On Biologics, Biogenerics, Biosimilars]
|
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
HSMN NewsFeed,
29 May 2008:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
HSMN NewsFeed,
27 May 2008:
Biopharmaceuticals
[Alnylam Pharmaceuticals, Takeda Pharmaceutical]
|
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
HSMN NewsFeed,
19 May 2008:
Biopharmaceuticals
[Biogen Idec]
|
Apoptos Inc. Raises $28 Million in Series A Financing
HSMN NewsFeed,
6 May 2008:
Biopharmaceuticals, Oncology, Venture Capital
[Apoptos Inc]
|
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
HSMN NewsFeed,
29 Apr 2008:
Biopharmaceuticals
[Genentech, Rituxan, rituximab, systemic lupus erythematosus]
|
Ceregene Announces Two Key Additions to Leadership Team
HSMN NewsFeed,
23 Apr 2008:
Biopharmaceuticals, Personnel
[Ceregene]
|
Cambria Pharmaceuticals Announces $5.4 Million Series A Financing
HSMN NewsFeed,
22 Apr 2008:
Biopharmaceuticals, Venture Capital
[Cambria Pharmaceuticals]
|
Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing
HSMN NewsFeed,
22 Apr 2008:
Biopharmaceuticals, Venture Capital
[Resolvyx Pharmaceuticals]
|
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
HSMN NewsFeed,
17 Apr 2008:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
HSMN NewsFeed,
15 Apr 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, Multiple Sclerosis]
|
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
HSMN NewsFeed,
15 Apr 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, interferon beta-1a, Multiple Sclerosis]
|
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
HSMN NewsFeed,
25 Mar 2008:
Biopharmaceuticals, Personnel
[Micromet , BiTE antibodies]
|
Samaritan Pharmaceuticals Acquires Commercialization Rights to Market and Distribute Abiogen's Cancer Drug Abioklad in Greece, Cyprus and Turkey
HSMN NewsFeed,
19 Mar 2008:
Biopharmaceuticals, Distribution
[Samaritan Pharmaceuticals, Abiogen Pharma, Abioklad]
|
Zimmer Holdings, Inc. Adds Robert Hagemann and Cecil Pickett to Board of Directors
HSMN NewsFeed,
17 Mar 2008:
Devices, Personnel
[Zimmer Holdings]
|
PanGenetics Raises 23 Million Euro in Series C Financing to Fund Clinical Advancement of Its Therapeutic Antibody Programs
HSMN NewsFeed,
5 Mar 2008:
Biopharmaceuticals, Venture Capital
[PanGenetics, CD40 antagonist, Nerve Growth Factor]
|
Targanta Strengthens Senior Management Team
HSMN NewsFeed,
4 Mar 2008:
Biopharmaceuticals, Personnel
[Targanta Therapeutics]
|
Tercica Announces Changes to Its Board of Directors and Management Team
HSMN NewsFeed,
29 Feb 2008:
Biopharmaceuticals, Personnel
[Tercica]
|
TyRx Pharma, Inc. Raises $25 Million in Private Financing
HSMN NewsFeed,
28 Feb 2008:
Biopharmaceuticals, Venture Capital
[TyRx Pharma]
|
Mylan Announces Appointment of Patrick Vink as Senior Vice President in New Position of Global Head of Biologics
HSMN NewsFeed,
26 Feb 2008:
Biopharmaceuticals, Personnel
[Mylan Laboratories]
|
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
HSMN NewsFeed,
25 Feb 2008:
Regenerative Medicine, Personnel
[t2cure]
|
Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia
HSMN NewsFeed,
14 Feb 2008:
Biopharmaceuticals, Cardiology
[Biogen Idec, Cardiokine, lixivaptan, heart failure, hyponatremia]
|
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
HSMN NewsFeed,
12 Feb 2008:
Biopharmaceuticals, Oncology
[Cell Therapeutics, Zevalin, Ibritumomab Tiuxetan, non-Hodgkin's lymphoma]
|
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
HSMN NewsFeed,
11 Feb 2008:
Biopharmaceuticals, Personnel
[Regulus Therapeutics]
|
Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
HSMN NewsFeed,
5 Feb 2008:
Biopharmaceuticals, Generics, FDA
[Insmed, Follow-On Biologics]
|
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
HSMN NewsFeed,
4 Feb 2008:
Biopharmaceuticals, Personnel
[Poniard Pharmaceuticals]
|
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
HSMN NewsFeed,
28 Jan 2008:
Biopharmaceuticals, Personnel
[Cylene Pharmaceuticals]
|
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
HSMN NewsFeed,
25 Jan 2008:
Biopharmaceuticals
[Genentech, Biogen Idec, Rituxan, rituximab, rheumatoid arthritis]
|
Samaritan Hires Expert Marketing Specialist to Build Up Southeast Europe Sales
HSMN NewsFeed,
22 Jan 2008:
Biopharmaceuticals, Personnel
[Samaritan Pharmaceuticals]
|
Dr. Manuel Worcel Appointed CEO and President of Cardiokine
HSMN NewsFeed,
22 Jan 2008:
Biopharmaceuticals, Personnel
[Cardiokine]
|
Teva to Acquire CoGenesys
HSMN NewsFeed,
22 Jan 2008:
Biopharmaceuticals, Mergers & Acquisitions
[Teva Pharmaceutical, CoGenesys, Human Genome Sciences]
|
Progentix Orthobiology B.V. Closes Series A Financing Round
HSMN NewsFeed,
22 Jan 2008:
Regenerative Medicine, Venture Capital
[Progentix Orthobiology]
|
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
HSMN NewsFeed,
14 Jan 2008:
Biopharmaceuticals, FDA, Gastroenterology
[Elan Corp, Biogen Idec, TYSABRI, natalizumab, Crohns disease]
|
Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech
HSMN NewsFeed,
8 Jan 2008:
Biopharmaceuticals, Ophthalmology, Licensing
[PDL BioPharma, Ophthotech, Biogen Idec, Macular Degeneration, Volociximab]
|
Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis
HSMN NewsFeed,
7 Jan 2008:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, Multiple Sclerosis]
|
Tempo Pharmaceuticals Closes $8 Million in Series B Funding
HSMN NewsFeed,
3 Jan 2008:
Biopharmaceuticals, Venture Capital
[Tempo Pharmaceuticals]
|
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
HSMN NewsFeed,
27 Dec 2007:
Biopharmaceuticals, Dermatology, Personnel
[Manhattan Pharmaceuticals]
|
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
HSMN NewsFeed,
27 Dec 2007:
Biopharmaceuticals, Acquisitions
[Cell Therapeutics, Biogen Idec, Zevalin, ibritumomab tiuxetan]
|
Biogen Idec Announces First Startup in Its Innovation Incubator
HSMN NewsFeed,
19 Dec 2007:
Biopharmaceuticals
[Biogen Idec, bi3, Escoublac]
|
Alnylam Appoints Barry Greene President and Chief Operating Officer
HSMN NewsFeed,
14 Dec 2007:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
HSMN NewsFeed,
3 Dec 2007:
Biopharmaceuticals, Personnel
[Regulus Therapeutics, Alnylam Pharmaceuticals, Isis Pharmaceuticals]
|
APT Pharmaceuticals Expands Management Team
HSMN NewsFeed,
19 Nov 2007:
Biopharmaceuticals, Personnel
[APT Pharmaceuticals]
|
Alnylam Expands Management Team with New Appointments
HSMN NewsFeed,
16 Nov 2007:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
HSMN NewsFeed,
8 Nov 2007:
Biopharmaceuticals, Personnel
[Jennerex Biotherapeutics]
|
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
HSMN NewsFeed,
8 Nov 2007:
Biopharmaceuticals, Oncology, Personnel
[Cell Therapeutics]
|
Altus Pharmaceuticals Announces Management Changes
HSMN NewsFeed,
29 Oct 2007:
Biopharmaceuticals, Personnel
[Altus Pharmaceuticals]
|
Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
HSMN NewsFeed,
19 Oct 2007:
Biopharmaceuticals, Regulatory, Generics
[Hospira, Retacrit, epoetin zeta, anemia, epoetin alfa]
|
Metastatix Appoints Carol G. Gallagher, Pharm.D. as President and Chief Executive Officer
HSMN NewsFeed,
16 Oct 2007:
Biopharmaceuticals, Personnel
[Metastatix]
|
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
HSMN NewsFeed,
15 Oct 2007:
Biopharmaceuticals, Gastroenterology, FDA
[Elan Corp, Biogen Idec, TYSABRI, natalizumab, Crohns disease]
|
Elan Update
HSMN NewsFeed,
15 Oct 2007:
Biopharmaceuticals
[Elan Corp, Biogen Idec, TYSABRI]
|
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
HSMN NewsFeed,
11 Oct 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, Multiple Sclerosis]
|
Optherion, Inc. Completes $37 Million Start Up Financing
HSMN NewsFeed,
9 Oct 2007:
Biopharmaceuticals, Ophthalmology, Venture Capital
[Optherion]
|
GlobeImmune Raises $41.2 Million in Series C Financing
HSMN NewsFeed,
26 Sep 2007:
Biopharmaceuticals, Venture Capital
[GlobeImmune, Tarmogen]
|
Nephros Raises $12.7 Million in New Financing
HSMN NewsFeed,
25 Sep 2007:
Devices, Venture Capital
[Nephros, Hemodiafiltration, End-Stage Renal Disease]
|
Nodality Names David R. Parkinson, MD as Its CEO
HSMN NewsFeed,
24 Sep 2007:
Diagnostics, Personnel
[Nodality]
|
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed,
24 Sep 2007:
Biopharmaceuticals, Personnel
[Shire plc, Human Genetic Therapies]
|
Alnylam Announces the Termination of its Collaboration with Merck & Co., Inc.
HSMN NewsFeed,
19 Sep 2007:
Biopharmaceuticals
[Alnylam Pharmaceuticals, Merck]
|
PhotoMedex Hires Paul TanPiengco as Director of Marketing
HSMN NewsFeed,
18 Sep 2007:
Devices, Personnel
[PhotoMedex]
|
CEO and President David Brand to Leave Cardiokine
HSMN NewsFeed,
17 Sep 2007:
Biopharmaceuticals, Personnel
[Cardiokine]
|
FDA Informs Endo and Vernalis That New Target Action Date on Frova(R) sNDA Is Sept. 30, 2007
HSMN NewsFeed,
10 Sep 2007:
Biopharmaceuticals, FDA
[Endo Pharmaceuticals, Vernalis, FROVA, frovatriptan]
|
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
HSMN NewsFeed,
4 Sep 2007:
Biopharmaceuticals, Oncology
[Roche Group, Tarceva, erlotinib, non-small cell lung cancer]
|
Vical Names Andrew de Guttadauro Vice President, Corporate Development
HSMN NewsFeed,
20 Aug 2007:
Biopharmaceuticals, Personnel
[Vical Inc]
|
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
HSMN NewsFeed,
20 Aug 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis]
|
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
HSMN NewsFeed,
16 Aug 2007:
Biopharmaceuticals, Acquisitions, Oncology
[Cell Therapeutics, Biogen Idec, Zevalin, ibritumomab tiuxetan, NHL]
|
Phase II Clinical Trial Results for ADENTRI Published in Journal of the American College of Cardiology
HSMN NewsFeed,
14 Aug 2007:
Biopharmaceuticals, Cardiology
[Biogen Idec, ADENTRI, A1 adenosine receptor antagonist]
|
Biogen Idec Names Paul J. Clancy Chief Financial Officer
HSMN NewsFeed,
9 Aug 2007:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
HSMN NewsFeed,
8 Aug 2007:
Diagnostics, Oncology
[Xenomics, Acute Myeloid Leukemia]
|
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
HSMN NewsFeed,
31 Jul 2007:
Biopharmaceuticals, Gastroenterology, FDA
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, Crohn's Disease]
|
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
HSMN NewsFeed,
30 Jul 2007:
Biopharmaceuticals, Devices, Drug Delivery, Neurology
[Alnylam Pharmaceuticals, Medtronic, RNA Interference, Huntington's disease]
|
Alnylam Expands Management Team with New Appointments
HSMN NewsFeed,
24 Jul 2007:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
HSMN NewsFeed,
23 Jul 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI natalizumab, multiple sclerosis]
|
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
HSMN NewsFeed,
19 Jul 2007:
Biopharmaceuticals, Gastroenterology, Regulatory
[Elan Corp, Biogen Idec, TYSABRI, natalizumab, Crohn's disease]
|
Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations
HSMN NewsFeed,
10 Jul 2007:
Biopharmaceuticals, Personnel
[Cylene Pharmaceuticals]
|
Roche and Alnylam Form Major Alliance on RNAi Therapeutics
HSMN NewsFeed,
9 Jul 2007:
Biopharmaceuticals
[Roche Group, Alnylam Pharmaceuticals, RNAi, RNA interference]
|
Merck Names Peter Kellogg as Executive Vice President and Chief Financial Officer
HSMN NewsFeed,
29 Jun 2007:
Biopharmaceuticals, Personnel
[Merck]
|
Biogen Idec Announces Management Change
HSMN NewsFeed,
29 Jun 2007:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
NUCRYST Pharmaceuticals appoints Katherine J. Turner, PhD to Vice President, Research and Development
HSMN NewsFeed,
27 Jun 2007:
Biopharmaceuticals, Personnel
[NUCRYST Pharmaceuticals]
|
Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection
HSMN NewsFeed,
26 Jun 2007:
Biopharmaceuticals
[Alnylam Pharmaceuticals, ALN-RSV01, Respiratory Syncytial Virus]
|
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
HSMN NewsFeed,
26 Jun 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, UCB, CDP323, multiple sclerosis]
|
Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics
HSMN NewsFeed,
25 Jun 2007:
Biopharmaceuticals, Personnel
[Insmed]
|
Progen Expands Senior Management Team with Addition of Two Biopharmaceutical Industry Veterans
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Oncology, Personnel
[Progen Pharmaceuticals]
|
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
HSMN NewsFeed,
11 Jun 2007:
Biopharmaceuticals, Oncology
[Sunesis Pharmaceuticals, SNS-595, SNS-032, Leukemia]
|
Abbott and Caprion Extend Partnership to Discover Antibody Targets for Cancer
HSMN NewsFeed,
6 Jun 2007:
Biopharmaceuticals, Oncology
[Abbott, Caprion Proteomics, Thallion Pharmaceuticals, CellCarta]
|
NUCRYST Pharmaceuticals appoints Edward Gaj Jr. Vice President, Corporate Development
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Personnel
[NUCRYST Pharmaceuticals]
|
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology
[GlaxoSmithKline, BEXXAR, Tositumomab, 131I, non-Hodgkin's lymphoma]
|
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology
[Biogen Idec, Zevalin, Ibritumomab tiuxetan, radioimmunotherapy, lymphoma]
|
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
HSMN NewsFeed,
3 Jun 2007:
Biopharmaceuticals, Oncology
[sanofi-aventis, Oxford BioMedica , TroVax, renal cell carcinoma]
|
Millennium Appoints Three New Members to Executive Management Team
HSMN NewsFeed,
1 Jun 2007:
Biopharmaceuticals, Personnel
[Millennium Pharmaceuticals]
|
Peter M. Strumph Named CEO of Nile Therapeutics
HSMN NewsFeed,
31 May 2007:
Biopharmaceuticals, Personnel
[Nile Therapeutics]
|
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
HSMN NewsFeed,
29 May 2007:
Biopharmacetuicals, Gastroenterology, FDA
[Elan Corp, Biogen Idec, TYSABRI, natalizumab, Crohn's disease]
|
Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding
HSMN NewsFeed,
23 May 2007:
Biopharmaceuticals, Venture Capital
[Tempo Pharmaceuticals]
|
Cougar Biotechnology Announces Additions to Clinical Research and Development Team
HSMN NewsFeed,
15 May 2007:
Biopharmaceuticals, Oncology, Personnel
[Cougar Biotechnology]
|
Tulip BioMed Appoints New President and Chief Operating Officer; Chief Financial Officer Adds Secretary and Treasurer Titles
HSMN NewsFeed,
9 May 2007:
Devices, Personnel
[Tulip BioMed]
|
Biogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease
HSMN NewsFeed,
8 May 2007:
Biopharmaceuticals, Neurology
[Vernalis, Biogen Idec, BIIB014, V2006, Parkinson's disease,]
|
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
HSMN NewsFeed,
3 May 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan Corp, TYSABRI, natalizumab, multiple sclerosis]
|
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
HSMN NewsFeed,
1 May 2007:
Biopharmaceuticals, Neurology
[Genentech, Biogen Idec, Rituxan, rituximab, multiple sclerosis]
|
Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
HSMN NewsFeed,
17 Apr 2007:
Biopharmaceuticals, Oncology
[Alnylam Pharmaceuticals, ALN-VSP01, RNA interference, liver cancer]
|
Dr. Paul A. Foster Joins Reata as Chief Medical Officer
HSMN NewsFeed,
16 Apr 2007:
Biopharmaceuticals, Personnel
[Reata Pharmaceuticals]
|
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
HSMN NewsFeed,
13 Apr 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, Interferon beta-1a, multiple sclerosis]
|
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
HSMN NewsFeed,
16 Mar 2007:
Biopharmaceuticals, FDA
[Endo Pharmaceuticals, Vernalis, Frova , frovatriptan, menstrual migraine]
|
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
HSMN NewsFeed,
12 Mar 2007:
Biopharmaceuticals, Neurology
[PDL BioPharma, CHOICE trial, daclizumab, multiple sclerosis]
|
ImmunoGen, Inc. Announces Departure of Walter Blattler
HSMN NewsFeed,
6 Mar 2007:
Biopharmaceuticals, Personnel
[ImmunoGen]
|
Oncologic Appoints Stephen T. Isaacs as President and Chief Executive Officer
HSMN NewsFeed,
6 Mar 2007:
Biopharmaceuticals, Oncology, Personnel
[Oncologic Inc]
|
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
HSMN NewsFeed,
7 Feb 2007:
Biopharmaceuticals, Oncology, FDA
[Biogen Idec, lumiliximab, fast track, chronic lymphocytic leukemia]
|
IRIS Submits 510(k) Application To FDA For Its N.A.D.I.A. Prostate Cancer Test
HSMN NewsFeed,
7 Feb 2007:
Diagnostics, Oncology, FDA
[IRIS International, Prostate-Specific Antigen, Prostate Cancer]
|
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed,
25 Jan 2007:
Biopharmaceuticals, Oncology
[Biogen Idec, galiximab, Non-Hodgkin's Lymphoma]
|
Kenneth M. Bate Named CEO of NitroMed
HSMN NewsFeed,
22 Jan 2007:
Biopharmaceuticals, Personnel
[NitroMed]
|
Proteolix Elects Dr. Michael Kauffman Chairman of the Board
HSMN NewsFeed,
17 Jan 2007:
Biopharmaceuticals, Oncology, Personnel
[Proteolix, proteasome]
|
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
HSMN NewsFeed,
9 Jan 2007:
Biopharmaceuticals, Neurology
[Biogen Idec, BG-12, multiple sclerosis]
|
Alnylam Announces Key Product and Business Goals for 2007
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals
[Alnylam Pharmaceuticals]
|
Biogen Idec to Acquire Syntonix
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Mergers & Acquisitions
[Biogen Idec, Syntonix, factor IX, hemophilia]
|
NovaCardia Appoints John E. Crawford as Chief Financial Officer
HSMN NewsFeed,
4 Jan 2007:
Biopharmaceuticals, Cardiology, Personnel
[NovaCardia]
|
Ventana Medical Systems Announces Court of Appeal Decision
HSMN NewsFeed,
29 Dec 2006:
Diagnostics, Litigation
[Ventana Medical Systems, BioGenex Laboratories]
|
ImmunoGen, Inc. Announces that sanofi-aventis Has Entered into an Option Agreement for Expanded Access to the Company's TAP Technology
HSMN NewsFeed,
26 Dec 2006:
Biopharmaceuticals, Drug Delivery, Licensing
[ImmunoGen, Tumor-Activated Prodrug, sanofi-aventis]
|
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
HSMN NewsFeed,
15 Dec 2006:
Biopharmaceuticals, Gastroenterology, FDA
[Elan , Biogen Idec, TYSABRI, natalizumab, Crohn's disease]
|
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
HSMN NewsFeed,
12 Dec 2006:
Biopharmaceuticals, Oncology
[Genentech, Avastin, bevacizumab, renal cell carcinoma]
|
Intranasal Therapeutics, Inc. Adds Key Executives to Management Team
HSMN NewsFeed,
6 Dec 2006:
Biopharmaceuticals, Drug Delivery, Personnel
[Intranasal Therapeutics]
|
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
HSMN NewsFeed,
5 Dec 2006:
Biopharmaceuticals
[Alnylam Pharmaceuticals, RNAi therapeutic, hypercholesterolemia, PCSK9]
|
Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
HSMN NewsFeed,
28 Nov 2006:
Biopharmaceuticals
[Alnylam Pharmaceuticals, RNAi, respiratory syncytial virus]
|
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
HSMN NewsFeed,
21 Nov 2006:
Biopharmaceuticals, Personnel
[Altus Pharmaceuticals]
|
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed,
20 Nov 2006:
Biopharmaceuticals, Personnel
[Anadys Pharmaceuticals]
|
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed,
16 Nov 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Herceptin, Trastuzumab, HER2, breast cancer]
|
Kosan Appoints Robert De Jager as Chief Medical Officer
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals, Oncology, Personnel
[Kosan Biosciences]
|
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
HSMN NewsFeed,
24 Oct 2006:
Biopharmaceuticals, Gastroenterology
[Elan , Biogen Idec, TYSABRI, natalizumab, Crohn's disease]
|
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
HSMN NewsFeed,
20 Oct 2006:
Biopharmaceuticals, Neurology, FDA
[Biogen Idec, AVONEX, Interferon beta-1a, multiple sclerosis]
|
New Landmark Study Shows the Use of a BiovaxID Formulation Improves Disease Free survival in 80% of Patients Whose Cancer has Relapsed after Chemotherapy Administered With or Without Rituxan
HSMN NewsFeed,
19 Oct 2006:
Biopharmaceuticals, Oncology
[Accentia Biopharmaceuticals, BiovaxID, Idiotype vaccine, Non-Hodgkins Lymphoma]
|
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
HSMN NewsFeed,
11 Oct 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Avastin, bevacizumab, non-small cell lung cancer]
|
RHEI Pharmaceuticals Appoints Timothy M. Kish President and CFO
HSMN NewsFeed,
11 Oct 2006:
Biopharmaceuticals, Personnel
[RHEI Pharmaceuticals]
|
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
HSMN NewsFeed,
6 Oct 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, Multiple Sclerosis]
|
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
HSMN NewsFeed,
4 Oct 2006:
Biopharmaceuticals, Oncology
[Biogen Idec, Schering AG, Zevalin, Ibritumomab Tiuxetan, ZEAL trial]
|
Amicus Therapeutics Appoints Chief Financial Officer
HSMN NewsFeed,
2 Oct 2006:
Biopharmaceuticals, Personnel
[Amicus Therapeutics]
|
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Biogen Idec, Rituxan, Rituximab, non-Hodgkin's lymphoma]
|
Alnylam Announces Management Transition Plan in Business Development
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Personnel
[Alnylam Pharmaceuticals]
|
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, Interferon beta-1a, multiple sclerosis]
|
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
HSMN NewsFeed,
29 Sep 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
HSMN NewsFeed,
28 Sep 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, interferon beta-1a, multiple sclerosis]
|
Neose Provides Update on GlycoPEG-GCSF Program
HSMN NewsFeed,
22 Sep 2006:
Biopharmaceuticals, Oncology
[Neose Technologies, GlycoPEG-GCSF, Neutropenia]
|
Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML)
HSMN NewsFeed,
20 Sep 2006:
Biopharmaceuticals, Neurology
[Alnylam Pharmaceuticals, Biogen Idec, progressive multifocal leukoencephalopathy]
|
Targanta Appoints Mark Leuchtenberger, Former President and CEO of Therion Biologics Corporation, as President and CEO
HSMN NewsFeed,
18 Sep 2006:
Biopharmaceuticals, Personnel
[Targanta Therapeutics]
|
Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
HSMN NewsFeed,
14 Sep 2006:
Biopharmaceuticals, Licensing
[Biogen Idec, mondoBIOTECH AG, Aviptadil, Pulmonary Arterial Hypertension]
|
ADVENTRX Announces Senior Management Changes
HSMN NewsFeed,
8 Sep 2006:
Biopharmaceuticals, Personnel
[ADVENTRX Pharmaceuticals]
|
BioGenex Names Medical Technology Executive Raymond W. Cohen to Board of Directors
HSMN NewsFeed,
8 Sep 2006:
Diagnostics, Personnel
[BioGenex]
|
PDL BioPharma Announces Roche Discontinuation of Co-Development of Daclizumab in Asthma
HSMN NewsFeed,
30 Aug 2006:
Biopharmaceuticals
[PDL BioPharma, Roche , daclizumab, asthma]
|
Magen BioSciences, Inc. Raises $15.4 Million in Funding
HSMN NewsFeed,
28 Aug 2006:
Biopharmaceuticals, Dermatology, Venture Capital
[Magen BioSciences]
|
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed,
28 Aug 2006:
Biopharmaceuticals, Neurology
[Genentech, Biogen Idec, Rituxan, Rituximab, multiple sclerosis]
|
Biogen Idec Researchers Identify Potential New Pathway in Rheumatoid Arthritis Disease Process
HSMN NewsFeed,
15 Aug 2006:
Biopharmaceuticals
[Biogen Idec, rheumatoid arthritis, tumor necrosis factor]
|
IDM Pharma Appoints Sylvie Gregoire, Pharm. D., as Executive Chair of the Board of Directors
HSMN NewsFeed,
15 Aug 2006:
Biopharmaceuticals, Personnel
[IDM Pharma]
|
Cabrellis Pharmaceuticals Raises $27.5 Million in Series A Funding
HSMN NewsFeed,
7 Aug 2006:
Biopharmaceuticals, Venture Capital
[Cabrellis Pharmaceuticals, Calsed, anthracycline, Conforma Therapeutics]
|
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed,
24 Jul 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
Poniard Pharmaceuticals Appoints Alan B. Glassberg, M.D., as Chief Medical Officer
HSMN NewsFeed,
20 Jul 2006:
Biopharmaceuticals, Personnel
[Poniard Pharmaceuticals]
|
Endo Pharmaceuticals and Vernalis plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Menstrual Migraine
HSMN NewsFeed,
19 Jul 2006:
Biopharmaceuticals, FDA
[Vernalis, Endo Pharmaceuticals, Frova , frovatriptan, menstrual migraine]
|
Dr. Harold Handley Appointed President of Aethlon Medical, Inc.
HSMN NewsFeed,
18 Jul 2006:
Devices, Personnel
[Aethlon Medical, Hemopurifier]
|
Biogen Idec Names Cecil B. Pickett President, Research & Development
HSMN NewsFeed,
12 Jul 2006:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Schering-Plough Announces Executive Changes in Schering-Plough Research Institute
HSMN NewsFeed,
12 Jul 2006:
Biopharmaceuticals, Personnel
[Schering-Plough]
|
ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics
HSMN NewsFeed,
11 Jul 2006:
Biopharmaceuticals, Licensing
[ImmunoGen, Biotest AG, Tumor-Activated Prodrug]
|
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
HSMN NewsFeed,
6 Jul 2006:
Biopharmaceuticals, Personnel
[Alexion Pharmaceuticals]
|
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
HSMN NewsFeed,
30 Jun 2006:
Biopharmaceuticals, Personnel
[OXiGENE]
|
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
HSMN NewsFeed,
29 Jun 2006:
Biopharmaceuticals, Regulatory, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed,
27 Jun 2006:
Biopharmaceuticals, Oncology
[Genentech, Avastin, bevacizumab, pancreatic cancer]
|
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
HSMN NewsFeed,
22 Jun 2006:
Biopharmaceuticals
[Genentech, Rituxan, Rituximab, Rheumatoid Arthritis]
|
Mark Matthews Joins Javelin Pharmaceuticals as VP of Commercial Affairs
HSMN NewsFeed,
21 Jun 2006:
Biopharmaceuticals, Personnel
[Javelin Pharmaceuticals]
|
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
HSMN NewsFeed,
20 Jun 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Avastin, bevacizumab, 5-fluorouracil, colorectal cancer]
|
AVONEX(R), The Most Prescribed Multiple Sclerosis Therapy Worldwide, May Now Be Given with Smaller Needle
HSMN NewsFeed,
20 Jun 2006:
Biopharmaceuticals, Drug Delivery, Neurology
[Biogen Idec, AVONEX, Interferon beta, multiple sclerosis]
|
Clinical Data on Volociximab (M200) Presented at the American Society of Clinical Oncology Annual Meeting
HSMN NewsFeed,
6 Jun 2006:
Biopharmaceuticals, Oncology
[PDL BioPharma, Biogen Idec, volociximab, M200]
|
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, Oncology
[Genentech, OSI Pharmaceuticals, Avastin, Tarceva, bevacizumab, erlotinib]
|
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed,
5 Jun 2006:
Biopharmaceuticals, FDA, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
Archemix Corp. Strengthens its Board of Directors Adding Alnylam President and CEO, John Maraganore, Ph.D.
HSMN NewsFeed,
31 May 2006:
Biopharmaceuticals, Personnel
[Archemix]
|
Biogen Idec to Acquire Fumapharm AG
HSMN NewsFeed,
31 May 2006:
Biopharmaceuticals, Mergers & Acquisitions
[Biogen Idec, Fumapharm, BG-12, multiple sclerosis]
|
Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed,
30 May 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, BG-12, multiple sclerosis]
|
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
HSMN NewsFeed,
25 May 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Avastin, bevacizumab, Breast Cancer]
|
Clera Announces Senior Management Appointments
HSMN NewsFeed,
23 May 2006:
Biopharmaceuticals, Personnel
[ Clera Inc]
|
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed,
23 May 2006:
Biopharmaceuticals, Oncology
[Genentech, Roche , AVANT trial, Avastin, XELOX, FOLFOX, colon cancer]
|
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
HSMN NewsFeed,
19 May 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, Interferon beta-1a, multiple sclerosis]
|
Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team
HSMN NewsFeed,
17 May 2006:
Biopharmaceuticals, Oncology, Personnel
[Cabrellis Pharmaceuticals, Conforma Therapeutics, amrubicin]
|
MorphoSys and Schering-Plough Sign R&D Agreement
HSMN NewsFeed,
17 May 2006:
Biopharmaceuticals
[MorphoSys , Schering-Plough, Combinatorial Antibody Library, HuCAL]
|
Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of Legal Affairs
HSMN NewsFeed,
15 May 2006:
Biopharmaceuticals, Personnel
[Somaxon Pharmaceuticals]
|
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
HSMN NewsFeed,
8 May 2006:
Biopharmaceuticals
[Endo Pharmaceuticals, Vernalis, Frova, frovatriptan, menstrual migraine]
|
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
HSMN NewsFeed,
4 May 2006:
Biopharmaceuticals
[ImmunoGen, Genentech]
|
Biogen Idec to Expand Oncology Pipeline with Acquisition of Conforma Therapeutics
HSMN NewsFeed,
3 May 2006:
Biopharmaceuticals, Oncology, Mergers & Acquisitions
[Biogen Idec, Conforma Therapeutics]
|
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed,
28 Apr 2006:
Biopharmaceuticals, Neurology, Regulatory
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
Stephen Tulipano Joins Javelin Pharmaceuticals as Chief Financial Officer
HSMN NewsFeed,
24 Apr 2006:
Biopharmaceuticals, Personnel
[Javelin Pharmaceuticals]
|
ArQule Announces Management and Board Changes
HSMN NewsFeed,
13 Apr 2006:
Biopharmaceuticals, Personnel
[ArQule]
|
Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
HSMN NewsFeed,
11 Apr 2006:
Biopharmaceuticals, Oncology
[Genentech, Avastin, bevacizumab, Non-Small Cell Lung Cancer]
|
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
HSMN NewsFeed,
10 Apr 2006:
Biopharmaceuticals, Personnel
[Genentech]
|
New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
HSMN NewsFeed,
6 Apr 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , multiple sclerosis, TYSABRI, natalizumab]
|
Life Science Angels Invests in NeuroHealing Pharmaceuticals
HSMN NewsFeed,
5 Apr 2006:
Biopharmaceuticals, Venture Capital
[Life Science Angels, NeuroHealing Pharmaceuticals]
|
Astellas to Acquire AMEVIVE(R) (alefacept)
HSMN NewsFeed,
3 Apr 2006:
Biopharmaceuticals, Dermatology, Acquisitions
[Biogen Idec, Astellas Pharma US, AMEVIVE , alefacept]
|
Newly Published Data Show Early Use of AVONEX(R) Delayed the Risk of Multiple Sclerosis for up to 5 Years
HSMN NewsFeed,
3 Apr 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, AVONEX, multiple sclerosis]
|
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
HSMN NewsFeed,
30 Mar 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Biogen Idec, Rituxan, rituximab, non-Hodgkin's lymphoma]
|
David Parkinson, MD Joins Biogen Idec as Head of Oncology Research and Development
HSMN NewsFeed,
29 Mar 2006:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
HSMN NewsFeed,
29 Mar 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and Sales
HSMN NewsFeed,
29 Mar 2006:
Biopharmaceuticals, Personnel
[Acusphere]
|
National Stem Cell, Inc. Intends to Merge with Azurel, Ltd.
HSMN NewsFeed,
28 Mar 2006:
Regenerative Medicine, Mergers & Acquisitions
[National Stem Cell, Azurel]
|
Carol G. Gallagher, Pharm. D., to Join Anadys Pharmaceuticals as Vice President, Commercial Affairs
HSMN NewsFeed,
22 Mar 2006:
Biopharmaceuticals, Personnel
[Anadys Pharmaceuticals]
|
Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI(R) for Multiple Sclerosis
HSMN NewsFeed,
22 Mar 2006:
Biopharmaceuticals, FDA, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
NitroMed Board Appoints New Senior Management
HSMN NewsFeed,
21 Mar 2006:
Biopharmaceuticals, Personnel
[NitroMed]
|
Genentech Provides Updates at Annual Investment Meeting
HSMN NewsFeed,
17 Mar 2006:
Biopharmaceuticals
[Genentech]
|
TRACON Pharmaceuticals Assembles Industry-Leading Management Team to Support Development of Targeted Cancer Therapy Pipeline
HSMN NewsFeed,
15 Mar 2006:
Biopharmaceuticals, Personnel
[TRACON Pharmaceuticals]
|
IDM and Medison Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in Israel
HSMN NewsFeed,
14 Mar 2006:
Biopharmaceuticals, Distribution, Licensing
[IDM Pharma, Medison Pharma, Junovan]
|
FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed,
8 Mar 2006:
Biopharmaceuticals, Neurology, FDA
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine
HSMN NewsFeed,
1 Mar 2006:
Biopharmaceuticals, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
HSMN NewsFeed,
28 Feb 2006:
Biopharmaceuticals, FDA
[Genentech, Biogen Idec, Rituxan, Rituximab, methotrexate, rheumatoid arthritis]
|
Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID (TM), a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
HSMN NewsFeed,
22 Feb 2006:
Biopharmaceuticals, Oncology, FDA
[Accentia Biopharmaceuticals, Biovest, BiovaxID, Non-Hodgkin's Lymphoma]
|
IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe
HSMN NewsFeed,
21 Feb 2006:
Biopharmaceuticals, Licensing
[IDM Pharma, GENESIS Pharma, Junovan]
|
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin(R) in Early-Stage HER2-Positive Breast Cancer
HSMN NewsFeed,
15 Feb 2006:
Biopharmaceuticals, Oncology, FDA
[Genentech, Herceptin, Trastuzumab, breast cancer]
|
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed,
13 Feb 2006:
Biopharmaceuticals, Oncology
[Genentech, AVANT trial, Avastin, bevacizumab, colon cancer]
|
Biogen Idec Names Susan H. Alexander as Executive Vice President and General Counsel
HSMN NewsFeed,
30 Jan 2006:
Biopharmaceuticals, Personnel
[Biogen Idec]
|
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed,
23 Jan 2006:
Biopharmaceuticals, FDA, Neurology
[Biogen Idec, Elan , TYSABRI, natalizumab, multiple sclerosis]
|
ZIOPHARM Appoints Senior Vice President for Technical Operations
HSMN NewsFeed,
19 Jan 2006:
Biopharmaceuticals, Personnel
[ZIOPHARM Oncology]
|
Corgentech Announces Management Promotions
HSMN NewsFeed,
19 Jan 2006:
Biopharmaceuticals, Personnel
[Corgentech]
|
Genentech Announces Executive Promotions
HSMN NewsFeed,
5 Jan 2006:
Biopharmaceuticals, Personnel
[Genentech]
|
|
|
 |
Additional items found:
The Network Archive contains
273 additional items
matching: Biogen
<< Members - click the icon at left to display. |
|
| |
|
|
|
|
Public
Feeds 
Full text >>